NHS v Servier: unlawful means tort claim fails, but the long-running saga continues

In this article, we summarise the Supreme Court’s judgment which upholds the lower courts’ decisions in refusing to allow the NHS to avail itself of the tort of unlawful means against Servier, and we comment on the reasoning of the Supreme Court.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Europe

UPC upholds injunction in Invisalign maker’s software dispute with rival

9 July 2026 China-headquartered Angelalign failed to convince UPC appellate judges to overturn a ban that affects its ability to offer orthodontic planning software in Europe with certain functionality.

Europe

BioNTech and Pfizer secure big European win over mRNA patent

8 July 2026 UPC judges revoke a patent asserted against the companies over their Comirnaty COVID-19 vaccine, in a ruling that clarified the court’s key principles on exclusive licences, novelty and inventive step.

Europe

UPC revives patent, but timing sinks Guardant’s appeal

6 July 2026 The Unified Patent Court delivers a mixed ruling in a dispute over liquid biopsy technology, overturning a finding that a patent was likely invalid while refusing to grant interim relief because of the patent owner’s delay.

More features

UPC upholds injunction in Invisalign maker’s software dispute with rival

BioNTech and Pfizer secure big European win over mRNA patent

UPC revives patent, but timing sinks Guardant’s appeal

HGF expands European offering with pair of in-house hires

What’s at stake in Australia’s biggest pharma patent appeal in years?

Will Mounjaro and Zepbound get their first US generic rival?

Merck KGaA agrees $11.3bn deal in major life sciences expansion

Novartis and Eli Lilly sign separate $1.9bn novel drug deals

NHS v Servier: unlawful means tort claim fails, but the long-running saga continues

More on this story

Editor's picks

Editor's picks

More features